---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-26-003566"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:55:23.886864+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NeOnc CEO buys ~$300k NTHI stock; FY2025 net loss $62M, mostly non-cash; clinical catalysts ahead

## Summary
- CEO Amir Heshmatpour purchased ~$300k of NTHI common stock in the past week, signaling confidence.
- FY2025 net loss ~$62M; ~$45.2M was non-cash stock comp ($35.6M) and one-time listing fees ($9.6M); normalized cash op ex ~$10.1M.
- NEO100 Phase 2a interim data readout expected ~August 2026 (within ~4 months).
- NEO212 Type B End-of-Phase FDA meeting within ~4 weeks to align on potential registrational Phase 2 study.
- Q1 2026 private placement raised ~$13M gross; proceeds used to repay convertible debt and obligations.

## SEC filing metadata
- accession: 0001829126-26-003566
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912626003566/0001829126-26-003566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912626003566/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-26-003566
- JSON: https://secwatch.observer/filing/0001829126-26-003566.json
- Plain text: https://secwatch.observer/filing/0001829126-26-003566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.